Abstract
Premature ejaculation is generally regarded the most frequent male ejaculatory complaint and has been considered a psychosexual disorder with psychogenic aetiology. The efficacy of various antidepressants, however, to delay ejaculation in men and to pharmacologically treat premature ejaculation suggests a strong neurobiological involvement. Most of our current understanding of the neurobiology and neuroanatomy of sexual behavior and ejaculatory function has been derived from preclinical studies using several laboratory species. In the present paper we will review the various animal models that have been developed to further study ejaculatory function in the laboratory rat. In addition, we will briefly review the effects of serotonergic antidepressants and serotonergic compounds on sexual and ejaculatory behavior. Together, these preclinical studies may contribute to a better understanding of the neurobiology of ejaculation and help the development of novel drug targets to treat ejaculatory disorders such as premature ejaculation.
Keywords: Premature ejaculation, animal model, SSRI, serotonine
Current Pharmaceutical Design
Title: Animal Models of Ejaculatory Behavior
Volume: 11 Issue: 31
Author(s): T. Pattij, B. Olivier and M. D. Waldinger
Affiliation:
Keywords: Premature ejaculation, animal model, SSRI, serotonine
Abstract: Premature ejaculation is generally regarded the most frequent male ejaculatory complaint and has been considered a psychosexual disorder with psychogenic aetiology. The efficacy of various antidepressants, however, to delay ejaculation in men and to pharmacologically treat premature ejaculation suggests a strong neurobiological involvement. Most of our current understanding of the neurobiology and neuroanatomy of sexual behavior and ejaculatory function has been derived from preclinical studies using several laboratory species. In the present paper we will review the various animal models that have been developed to further study ejaculatory function in the laboratory rat. In addition, we will briefly review the effects of serotonergic antidepressants and serotonergic compounds on sexual and ejaculatory behavior. Together, these preclinical studies may contribute to a better understanding of the neurobiology of ejaculation and help the development of novel drug targets to treat ejaculatory disorders such as premature ejaculation.
Export Options
About this article
Cite this article as:
Pattij T., Olivier B. and Waldinger D. M., Animal Models of Ejaculatory Behavior, Current Pharmaceutical Design 2005; 11 (31) . https://dx.doi.org/10.2174/138161205774913363
DOI https://dx.doi.org/10.2174/138161205774913363 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Meta-analysis and Approach of the Real Impact of Anorexigenic Drugs in the Obesity in Humans: The Last Five Years of the Randomized Studies
Current Diabetes Reviews Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals Animal Models of Maternal Immune Activation in Depression Research
Current Neuropharmacology Knowledge, Normative Beliefs and Attitudes Related to Recent HIV Infection among People who Inject Drugs in Athens, Greece
Current HIV Research The Mechanisms of Immune-to-Brain Communication in Inflammation as a Drug Target
Current Drug Targets - Inflammation & Allergy Migraine: Current Therapeutic Targets and Future Avenues
Current Vascular Pharmacology Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease
Vascular Disease Prevention (Discontinued) γ-AApeptides as a New Strategy for Therapeutic Development
Current Medicinal Chemistry Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets New Hope for the Diagnosis and Therapy of Alzheimers Disease
Protein & Peptide Letters How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The “LEARn” Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD
Current Alzheimer Research Molecular Targets in the Rational Design of AD Specific PET Tracers: Tau or Amyloid Aggregates?
Current Alzheimer Research Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review Focused on Molecular Mechanisms of Anxiolytic Effect of <i>Valerina officinalis</i> L. in Connection with Its Phytochemistry through <i>in vitro/in vivo</i> Studies
Current Pharmaceutical Design Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology γ-Secretase Modulation and its Promise for Alzheimers Disease: a Rationale for Drug Discovery
Current Topics in Medicinal Chemistry Pharmacokinetic Properties and In Silico ADME Modeling in Drug Discovery
Medicinal Chemistry Searching for Predictive Blood Biomarkers: Misfolded p53 In Mild Cognitive Impairment
Current Alzheimer Research